Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Niagen Bioscience, Inc.NAGE · Entity 6146 | SVP, General Counsel | June 30, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Niagen Bioscience, Inc.
Report date June 30, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,565 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 2,314 · Balance 4,565 F1: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d). |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 8, 2026 21:18 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantCommon Stock | 2,314 | $2.71 | $6,270.94 |
DisclosureSEC source: 0002042509-26-000001 · wk-form4_1783545518.xml · nonDerivative · entry 1 Lopez Carlos Luis · CIK 0002042509 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,565 F1 · kind: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d). Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 21:47 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 41,420 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0001628280-26-011162 · wk-form4_1771969645.xml · derivative · entry 1 Lopez Carlos Luis · CIK 0002042509 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,420 Underlying: Common Stock · 41,420 shares Expires 2036-02-18 F1 · derivative.exercise_date: One-fourth of the shares subject to the option shall vest on each anniversary of the grant date. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 12:11 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 273 | $7.86 | $2,145.78 |
DisclosureSEC source: 0001628280-25-011466 · wk-form4_1741608665.xml · nonDerivative · entry 1 Lopez Carlos Luis · CIK 0002042509 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,251 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:19 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 19,691 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0001628280-25-005858 · wk-form4_1739575167.xml · derivative · entry 1 Lopez Carlos Luis · CIK 0002042509 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,691 Underlying: Common Stock · 19,691 shares Expires 2035-02-11 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on February 12, 2026 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.